Immunicum has announced that effective immediately, Lotta Ferm will join the leadership team as interim Chief Financial Officer (CFO).
Lotta Ferm succeeding Peter Hein, who will leave at the end of February.
“As we rapidly advance our ongoing integration process, we welcome Lotta who has substantial experience with life science and biotech companies,” states Sven Rohmann, CEO of Immunicum. “We thank Peter for his support through our transaction and look forward to Lotta’s contribution while we build a strong foundation for our further growth.”
Nearly 30 years of finance and controlling experience
Lotta Ferm has nearly 30 years of finance and controlling experience from a range of corporations including most recently Doktor24 Healthcare AB and Medivir AB in the healthcare and life science sectors. She has held CFO, Head of Finance and Head of Controlling positions consistently over the last decade and led the corporate finance and accounting functions for multiple transitions for dynamic and innovative companies. She holds a degree in Business Administration and Economics from Kristianstad and Växjö University.